The Federal Trade Commission and the U.S. Department of Justice antitrust division have an additional 30 days to review the Novo Nordisk Foundation’s $16.5 billion acquisition of contract manufacturer Catalent, according to an SEC filing on Wednesday.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,